Spartan Medical Inc., a company owned by veterans and specializing in medical solutions, has initiated a comprehensive campaign to raise awareness regarding the serious repercussions of Surgical Site Infections (SSIs). Their mission is to mitigate the incidence of SSIs in medical facilities nationwide.

At the forefront of the battle against SSIs, Spartan Medical, Inc. adopts a dual-pronged strategy, striving to tackle this significant challenge through the provision of innovative sterile instruments and implants, as well as top-tier wound care products.

Surgical Site Infections pose a formidable challenge, contributing to an annual increase in healthcare expenditures of up to $10 billion and a substantial rise in morbidity and mortality rates. These infections afflict approximately 4.4% of all surgeries, with instrumented spinal surgeries experiencing a 6.6% SSI rate, including a staggering 4.9% rate of deep incisional SSIs, costing an average of $93,741 to treat.

The predominant source of SSIs lies in contaminated surgical instruments and implants, many of which are extremely difficult to clean thoroughly, leaving residual bone and tissue debris.

In response to this issue, Spartan Medical is actively developing a comprehensive range of single-use, sterile, pre-packaged (SSP) instruments and implants, exemplified by the groundbreaking Sure Retractor—the world's first and only SSP surgical retractor. Additionally, Spartan Medical has introduced its line of single-use, always-sharp kerrisons and has commenced distribution of a complete line of SSP spinal fusion products and instruments.

Even with the elimination of this primary source of infections through SSP instruments and implants, approximately one-third of SSIs stem from general operating theater conditions. Spartan Medical addresses this challenge by offering Imbed Biosciences' Microlyte® Matrix, an FDA-approved, next-generation, shelf-stable wound care product designed for surgical wound management. Microlyte® has exhibited the ability to eradicate a significant portion of infectious bacteria before SSIs can develop, remaining antimicrobial for more than three days within a surgical wound. Preclinical studies have demonstrated a remarkable reduction in surgical site bacterial counts and accelerated healing of clean surgical wounds. In a prospective clinical trial focusing on diabetic foot and ankle surgery, where the historical surgical site infection rate stood at 15%, no SSIs were reported among those treated with Microlyte® Matrix. In this study, the matrix was placed within the surgical wound before closing the skin with sutures or staples.

As the industry leader, employing a two-pronged approach encompassing both prevention and immediate elimination, Spartan Medical aims to significantly reduce the nearly twenty thousand Americans who succumb to SSIs each year. Spartan Medical continues to innovate tirelessly, committed to its mission of delivering top-tier medical products to our nation, with a particular focus on our honorable soldiers, veterans, and their families.

It is worth noting that all the referenced products and solutions are presently available under contract at VA and DoD Medical Centers across the country.

 

Source: prnewswire.com

Report Abuse